Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York. CEO Adelene Perkins will lead a fireside chat on November 29 at 4:00 p.m. ET, discussing the company’s lead product, eganelisib, an innovative oral immuno-oncology treatment for cancer. Investors can attend 1-on-1 meetings with Infinity representatives. A replay of the presentation will be available on Infinity's website for 90 days post-event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the Piper Sandler 34^th Annual Healthcare Conference taking place November 29 – December 1, 2022 in New York.

Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29, 2022
Time: 4:00 p.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
https://event.webcasts.com/starthere.jsp?ei=1584856&tp_key=e9a7246381

A replay of the presentation will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the event.

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005211/en/

Investor Relations:

Luke Heagle

Real Chemistry

lheagle@realchemistry.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

When is Infinity Pharmaceuticals presenting at the Piper Sandler 34th Annual Healthcare Conference?

Infinity Pharmaceuticals will present at the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022.

Who will represent Infinity Pharmaceuticals at the conference?

CEO Adelene Perkins will represent Infinity Pharmaceuticals at the conference.

What is eganelisib developed by Infinity Pharmaceuticals?

Eganelisib is a first-in-class oral immuno-oncology therapy designed to reprogram macrophages to combat cancer.

How can investors access Infinity Pharmaceuticals' presentation?

Investors can access a replay of the presentation on Infinity's website for 90 days following the event.

What is the significance of the MARIO studies for Infinity Pharmaceuticals?

The MARIO studies are crucial clinical trials assessing eganelisib's effectiveness in combination with other treatments for various cancer types.